| http://www.w3.org/ns/prov#value | - Future studies should assess the balanceof risk and benefit of treatment in this frail population, and they should be adequately poweredto assess both benefit and risk.Participants agreed that that there is a need for an FDA-approved indication for treatingdementia-related symptoms of severe and persistent or recurrent agitation and aggression, evenin the absence of psychosis.
|
